uniQure Investors Notified of Class Action Deadline by Faruqi & Faruqi, LLP

Class Action Alert for uniQure Investors

Faruqi & Faruqi, LLP, a distinguished national securities law firm, has issued an important reminder for investors holding shares in uniQure N.V. (NASDAQ: QURE). The firm is currently investigating potential claims against the company as part of an ongoing federal securities class action, with a crucial deadline set for April 13, 2026.

Background Information on uniQure

uniQure N.V. is a biopharmaceutical company dedicated to providing transformative gene therapies for patients with genetic diseases. Founded in 1998, uniQure has established itself in the field of gene therapy, with notable advancements and developments in their pipeline.

Recently, the firm disclosed major concerns surrounding the approval status of its pivotal study for AMT-130, a gene therapy for Huntington's disease. Reportedly, the FDA has indicated that the data from uniQure's prior studies might not be adequate for the Biologics License Application (BLA) submission, despite earlier assertions about the project's progress and promise.

Key Allegations

The class action complaint centers on the assertion that uniQure misled investors by making false statements or omissions regarding several critical factors:
1. FDA Approval Status: The FDA's approval which was previously believed to be firm for the Pivotal Study was called into question, suggesting that the design and its comparison to historical data weren't fully sanctioned by the agency.
2. Delay in BLA Timeline: There was a downplay of the risks regarding potential delays in the BLA timeline due to the necessity of additional studies, contradicting earlier portrayals of a rapidly advancing project.
3. Misleading Business Operations Statements: Overall, executives from uniQure allegedly provided reassurances about the business's prospects that lacked a reasonable basis in light of these emerging issues.

On November 3, 2025, investors were met with shocking news as uniQure revealed the FDA’s position, leading to a significant drop in share price—over 49% in just one day. This secondary disclosure fundamentally altered the investment landscape for many shareholders, resulting in substantial financial losses.

Role of Faruqi & Faruqi

Faruqi & Faruqi, known for their strong track record in securities litigation, encourages shareholders who experienced losses during the specified timeline (September 24, 2025, through October 31, 2025) to come forward and discuss their options. Prospective lead plaintiffs can step forward to ensure their voices are part of the collective legal remedy sought.

Faruqi & Faruqi asserts that individuals do not have to act as lead plaintiffs to benefit from a potential recovery; each participant's rights will be preserved regardless of involvement level.

The firm also invites anyone with relevant information regarding uniQure's alleged conduct to reach out, including whistleblowers, former employees, and interested shareholders.

How to Get Involved

Investors interested in exploring this matter further or potentially participating in the class action can learn more by visiting Faruqi & Faruqi's website or by contacting partner Josh Wilson directly at (877) 247-4292 or (212) 983-9330 (Ext. 1310).

As April 13, 2026, approaches, uniQure shareholders are urged to stay informed and consider their legal rights amidst the ongoing developments in this significant securities class action. Updates will be provided through social media platforms including LinkedIn, X, and Facebook—ensuring all potentially affected individuals are kept in the loop regarding their rights and remedies.